Recap: Tirzepatide Is Approved to Cut Cardiovascular Risk in Type 2 Diabetes

by AiNewsBlog Oct, 22

written by AiNewsBlog Oct, 22 0 comments

The FDA approved tirzepatide (Mounjaro; Eli Lilly and Company) to lower the risk of major adverse cardiovascular events (MACE)—cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke—in adults with type 2 diabetes (T2D) at high risk for these events.¹

AiNewsBlog

Leave a Comment Cancel Reply

Name	Price	7d %	Volume
Bitcoin btc	$81,707	0.93%	$38,259,807,376
Ethereum eth	$2,403	1.39%	$13,418,405,556
XRP xrp	$1.33	1.39%	$1,878,900,214
Solana sol	$104	2.07%	$2,874,726,290
Dogecoin doge	$0.079	-1.16%	$632,253,402

At Srivax, we believe in delivering fast, accurate, and relevant news to empower, inform, and engage our readers across the globe. We are an independent digital news platform built for the modern world — where information moves fast, and truth matters.